Schaeffer's Trading Floor Blog

Analyst Upgrades: Facebook Inc (FB), Delta Air Lines, Inc., and Gilead Sciences, Inc.

Analysts upwardly revised their ratings on FB, DAL, and GILD

by 7/24/2014 9:05 AM
Stocks quoted in this article:

Analysts are weighing in today on social networking guru Facebook Inc (NASDAQ:FB), airliner Delta Air Lines, Inc. (NYSE:DAL), and drug maker Gilead Sciences, Inc. (NASDAQ:GILD). Here's a quick roundup of today's bullish brokerage notes.

  • FB is headed for all-time highs, with the shares up 9.2% in pre-market trade. The company last night blew second-quarter earnings estimates out of the water, earning a bevy of subsequent upgrades and price-target hikes. Among the doting analysts were Topeka Capital and Jefferies, which both upped their price targets to $100, and J.P. Morgan Securities, which hiked its target by $10 to $90. On Wednesday, Facebook Inc settled at $71.29.

  • DAL saw its price target increased to $52 from $50 at UBS this morning. The shares of DAL are up 42.5% in 2014, and surged to $39.15 yesterday in the wake of a stronger-than-expected quarterly earnings report. The security is pointed modestly higher ahead of the bell, and the Federal Aviation Administration (FAA) this morning lifted its ban on U.S. airlines flying into Tel Aviv. DAL, which has indicated it may suspend flights to the region even longer than the FAA recommends, has yet to comment on the news. Most analysts were already in the bullish camp for Delta Air Lines, Inc., which boasts 11 "buy" or better endorsements, compared to one "hold" and not a single "sell" rating.

  • Finally, GILD -- like FB -- is on the verge of record-high territory. The shares are pointed 1.3% higher ahead of the bell, thanks to a regulatory win and a solid earnings showing. Specifically, the Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s Zydelig to treat a trio of blood cancers, and the drug maker last night said second-quarter earnings more than quadrupled from a year earlier, as Sovaldi sales surpassed estimates. GILD closed at $90.34 on Wednesday, and Cowen and Company, Guggenheim, and J.P. Morgan Securities expect the stock to journey into triple-digit territory; the brokerage firms hiked their respective price targets to $100, $120, and $110.

permanent link
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

Partner Center

© 2014 Schaeffer's Investment Research, Inc. 5151 Pfeiffer Road, Suite 250, Cincinnati, Ohio 45242 Phone: (800) 448-2080 FAX: (513) 589-3810 Int'l Callers: (513) 589-3800 Email: service@sir-inc.com

All Rights Reserved. Unauthorized reproduction of any SIR publication is strictly prohibited.

Market Data provided by QuoteMedia.com | Data delayed 15-20 minutes unless otherwise indicated.